HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Report from the 5th cardiovascular outcome trial (CVOT) summit.

Abstract
The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th-25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th-30th, 2020 (https://www.cvot.org).
AuthorsOliver Schnell, Eberhard Standl, Xavier Cos, Hiddo Jl Heerspink, Baruch Itzhak, Nebojsa Lalic, Michael Nauck, Antonio Ceriello
JournalCardiovascular diabetology (Cardiovasc Diabetol) Vol. 19 Issue 1 Pg. 47 (04 17 2020) ISSN: 1475-2840 [Electronic] England
PMID32303223 (Publication Type: Congress, Editorial)
Chemical References
  • Dipeptidyl-Peptidase IV Inhibitors
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Incretins
  • Sodium-Glucose Transporter 2 Inhibitors
Topics
  • Cardiovascular Diseases (diagnosis, epidemiology, prevention & control)
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 (diagnosis, drug therapy, epidemiology)
  • Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
  • Glucagon-Like Peptide-1 Receptor (agonists)
  • Humans
  • Incretins (adverse effects, therapeutic use)
  • Sodium-Glucose Transporter 2 Inhibitors (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: